
-
INmune Bio NasdaqCM:INMB INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Location: 225 NE Mizner Blvd., Boca Raton, FL, 33432, United States | Website: https://www.inmunebio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
151.8M
Cash
19.34M
Avg Qtr Burn
-8.177M
Short % of Float
38.59%
Insider Ownership
28.19%
Institutional Own.
25.67%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CORDStrom Details Recessive dystrophic epidermolysis bullosa | BLA Submission | |
Phase 2 Data readout | ||
INKmune™ Details Cancer, Prostate cancer, Castration-resistant prostate cancer Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
INB03 + trastuzumab-deruxtecan Details Cancer, Pancreatic cancer, Gastric cancer, HER2-expressing cancers, Breast cancer, Triple-negative breast cancer | Phase 2 Update | |
XPro1595 (XPro™) (pegipanermin fr) Details Major depressive disorder, Mental health, Treatment Resistant Depression | Phase 2 Initiation | |
INKmune™ Details Cancer, Myelodysplastic syndrome, Acute myeloid leukemia | Failed Discontinued | |
LIVNate Details Liver disease, NASH-induced significant or severe fibrosis | Failed Discontinued | |
Quellor™ Details COVID-19 | Failed Discontinued |